ISBT: COVID-19 Convalescent plasma document library

COVID-19 is an infectious disease that is caused by a new coronavirus, SARS-COV-2. The outbreak has affected almost every country of the World and as of June 16, 2020, a total of 8.058.427 confirmed cases and 437.532 deaths had been reported in 188 countries. As the development of efficient and safe vaccination will require months, quick alternative treatments are sought. Passive immunisation using the plasma of recovered COVID-19 donors for the treatment of severe COVID-19 cases could offer a suitable therapeutic strategy. The plasma of recovered COVID-19 donors contains specific IgG and IgM anti–SARS-CoV-19 antibodies, which can neutralize the virus. However, implementation of a convalescent plasma transfusion programme might need comprehensive planning.

ISBT aims to support those organisations who need guidance with developing their protocol for collecting and processing plasma for the treatment of COVID-19. Therefore, we prepared an open access platform for SHARING protocols from various WHO regions.

If your organisation has a protocol, guideline, guidance or a publication on the collection and processing of COVID-19 convalescent plasma, please upload the documents to share it with those, who might need your help.

Scroll down to submit your document.

Please find here the resources categorized by WHO region

International

Eastern Mediterranean

Europe

Western Pacific

Guide on the Compassionate Use of Convalescent Plasma Therapy For COVID-19, Philippines

Americas

Africa

A prospective cohort study of the collection of convalescent plasma from patients who have recovered from COVID-19 to be used as a treatment of passive antibodies against SARS-CoV-2- The PROTECT Trial

Submit your COVID-19 Convalescent Plasma Document

Submission form

Find here links to protocols or guidelines

The US national initiative to provide COVID-19 Convalescent Plasma for use in controlled trials and in expanded access linked to those trials: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19.
Details of the randomized, blinded controlled trials: https://ccpp19.org/
The FDA previously provided guidance on emergency use of COVID-19 convalescent plasma:
https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds

Disclaimer

The content of this resource does not necessarily reflect the views of the ISBT. Neither the ISBT nor any person acting on its behalf can be held responsible for any use that may be made of the information in the resource. While we endeavor to ensure that the information on this resource page is correct, we do not warrant the accuracy and completeness of the material.